Miscellaneous (add headline) Archives - Advanced Medical Solutions https://admedsol.com/message-type/miscellaneous-add-headline/ Mon, 02 Jun 2025 07:00:11 +0000 en-US hourly 1 https://wordpress.org/?v=6.9.4 https://admedsol.com/wp-content/uploads/2026/02/cropped-Web-Icon-32x32.png Miscellaneous (add headline) Archives - Advanced Medical Solutions https://admedsol.com/message-type/miscellaneous-add-headline/ 32 32 Appointment of Joint Corporate Broker https://admedsol.com/regulatory-news-announcements/7695637/ Mon, 02 Jun 2025 07:00:11 +0000 https://admedsol1stg.wpenginepowered.com/?post_type=rns-post&p=8970 RNS Number : 9007K Advanced Medical Solutions Grp PLC 02 June 2025   2 June 2025 Advanced Medical Solutions Group plc (“AMS” or the “Group” or the “Company”)   Appointment of Joint Corporate Broker   Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), a world-leading specialist in tissue-healing technologies, is pleased to announce the […]

The post Appointment of Joint Corporate Broker appeared first on Advanced Medical Solutions.

]]>

RNS Number : 9007K
Advanced Medical Solutions Grp PLC
02 June 2025
 

2 June 2025

Advanced Medical Solutions Group plc

(“AMS” or the “Group” or the “Company”)

 

Appointment of Joint Corporate Broker

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), a world-leading specialist in tissue-healing technologies, is pleased to announce the appointment of Joh. Berenberg, Gossler & Co KG, London Branch (“Berenberg”) as its joint Corporate Broker alongside Investec Bank plc, the Company’s current Corporate Broker and Nominated Adviser, with immediate effect.

 

– End –

 

For further information, please visit www.admedsol.com or contact:

 

Advanced Medical Solutions Group plc                                               Tel: +44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer

Michael King, Investor Relations

 

ICR Healthcare                                                                                     Tel: +44 (0) 20 3709 5700

Mary-Jane Elliott / Lucy Featherstone                                                     AMS@icrhealthcare.com

 

Investec Bank PLC (NOMAD & Joint Broker)                                         Tel: +44 (0) 20 7597 5970

Gary Clarence / David Anderson

 

Berenberg (Joint Broker)                                                                      Tel: +44 (0)20 3207 7800

Toby Flaux / Detlir Elezi / Yasmina Benchekroun

 

About Advanced Medical Solutions Group plc – see www.admedsol.com

 

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8®, LIQUIFIX™, Peters Surgical, Ifabond, Vitalitec and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made seven acquisitions: Sealantis, an Israeli developer of innovative internal sealants, Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business, Connexicon, an Irish tissue adhesives specialist, Syntacoll, a German specialist in collagen-based absorbable surgical implants and Peters Surgical, a global provider of specialty surgical sutures, mechanical haemostasis and internal cyanoacrylate devices.

 

AMS’s products, manufactured in the UK, Germany, France, the Netherlands, Thailand, India, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, Austria, France, Poland, Benelux, India, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 1,500 employees. For more information, please see www.admedsol.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 
 

MSCZZGGVVMNGKZM

The post Appointment of Joint Corporate Broker appeared first on Advanced Medical Solutions.

]]> Director/PDMR Shareholding https://admedsol.com/regulatory-news-announcements/7394513/ Tue, 06 May 2025 17:40:00 +0000 https://admedsol1stg.wpenginepowered.com/?post_type=rns-post&p=8912 RNS Number : 5671H Advanced Medical Solutions Grp PLC 06 May 2025       6 May 2025               Advanced Medical Solutions Group plc (“AMS”, the “Company” or the “Group”)               Director/PDMR Shareholding   Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, announces that on 30 […]

The post Director/PDMR Shareholding appeared first on Advanced Medical Solutions.

]]>

RNS Number : 5671H
Advanced Medical Solutions Grp PLC
06 May 2025
 

 

 

6 May 2025

 

            Advanced Medical Solutions Group plc

(“AMS”, the “Company” or the “Group”)

 

            Director/PDMR Shareholding

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, announces that on 30 April 2025, the Board, following a recommendation from its Remuneration Committee, granted new nil-cost share options to the following Directors/PDMRs under the existing Advanced Medical Solutions Long Term Incentive Plan (the ‘LTIP’). The vesting of these options is based on achieving certain performance criteria for the three years prior to vesting. The performance criteria under the LTIP scheme is split equally between Earnings Per Share (EPS) achievement against target and Total Shareholder Return (TSR) against a comparator group.  Directors/PDMRs are required to hold the LTIPs for a period of two years following vesting.

 

Director/PDMR

LTIPs prior to grant

LTIPs granted

Resultant LTIP holdings

Chris Meredith

Chief Executive Officer

1,257,692

 

438,194

 

1,695,886

Eddie Johnson

Chief Financial Officer

519,127

180,864

 

699,991

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name: Chris Meredith

2.

Reason for the notification

a)

Position/status: Chief Executive Officer

b)

Initial notification/Amendment: Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:   Advanced Medical Solutions Group plc

b)

LEI: 213800HJP6OWOSZI1L74

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument: Ordinary Shares of 5p

Identification code: GB0004536594

b)

Nature of the transactions:

-     Grant of LTIPs under the Advanced Medical Solutions Long Term Incentive Plan

c)

Price(s) and volume(s):

Sale of shares:

Price(s)

Volume(s)

1. –

438,194

d)

Aggregated information:

Aggregated volume: n/a

Aggregated price: n/a

e)

Date of the transaction: 30/04/2025

f)

Place of the transaction: Outside of a trading venue

 

 

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name: Eddie Johnson

2.

Reason for the notification

a)

Position/status: Chief Financial Officer

b)

Initial notification/Amendment: Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:   Advanced Medical Solutions Group plc

b)

LEI: 213800HJP6OWOSZI1L74

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument: Ordinary Shares of 5p

Identification code: GB0004536594

b)

Nature of the transactions:

-     Grant of LTIPs under the Advanced Medical Solutions Long Term Incentive Plan

c)

Price(s) and volume(s):

Sale of shares:

Price(s)

Volume(s)

1. –

180,864

d)

Aggregated information:

Aggregated volume: n/a

Aggregated price: n/a

e)

Date of the transaction: 30/04/2025

f)

Place of the transaction: Outside of a trading venue

 

 

– End –

 

For further information, please visit www.admedsol.com or contact:

 

Advanced Medical Solutions Group plc

Tel: +44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer

Michael King, Investor Relations



 

ICR Healthcare

Tel: +44 (0) 20 3709 5700

Mary-Jane Elliott / Lucy Featherstone

AMS@icrhealthcare.com



Investec Bank PLC (NOMAD & Broker)

Tel: +44 (0) 20 7597 5970

Gary Clarence / David Anderson




 

About Advanced Medical Solutions Group plc – see www.admedsol.com

 

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made five acquisitions: Sealantis, an Israeli developer of innovative internal sealants; Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business, Connexicon, an Irish tissue adhesives specialist, Syntacoll, a German specialist in collagen-based absorbable surgical implants and Peters Surgical, a global provider of specialty surgical sutures, mechanical haemostasis and internal cyanoacrylate devices.

AMS’s products, manufactured in the UK, Germany, France, the Netherlands, Thailand, India, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, Austria, France, Poland, Benelux, India, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 1,500 employees. For more information, please see www.admedsol.com.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 
 

MSCBLGDUSXGDGUL

The post Director/PDMR Shareholding appeared first on Advanced Medical Solutions.

]]>